News News
Your current location:
Homepage
>
>
>
The new technology of our company's "new anticoagulant ticagrelor" was included in the provincial key high...

The new technology of our company's "new anticoagulant ticagrelor" was included in the provincial key high...

  • Categories:Company News
  • Time of issue:2020-12-18 15:12
  • Views:

(Summary description)Recently, the Provincial Department of Economy and Information Technology listed Zhejiang Lepu Pharmaceutical's "new anticoagulant ticagrelor" new technology project in the "2020 Zhejiang High-tech Product Development Project".

The new technology of our company's "new anticoagulant ticagrelor" was included in the provincial key high...

(Summary description)Recently, the Provincial Department of Economy and Information Technology listed Zhejiang Lepu Pharmaceutical's "new anticoagulant ticagrelor" new technology project in the "2020 Zhejiang High-tech Product Development Project".

  • Categories:Company News
  • Time of issue:2020-12-18 15:12
  • Views:
Information

Recently, the Provincial Department of Economy and Information Technology listed Zhejiang Lepu Pharmaceutical's "new anticoagulant ticagrelor" new technology project in the "2020 Zhejiang High-tech Product Development Project".

In China, the antithrombotic drug market has great potential, with high incidence of cardiovascular disease, high mortality, and high recurrence rate. It has become one of the primary diseases that plagued Chinese residents. Now the antithrombotic drug market has become a hot topic in global drug development. One of the fields.

The new anticoagulant ticagrelor developed by our company is a new type of antithrombotic drug, which is mainly suitable for the treatment of acute coronary syndrome (ACS) and reduces the heart rate of ACS patients or patients with a history of myocardial infarction (MI). The incidence of vascular death, myocardial infarction, and stroke. After improving the production technology of the new anticoagulant ticagrelor, our company has solved the industrialization problem in the crystallization process. This process complies with the new standards of the international pharmaceutical industry. The green enzyme method is used to replace the traditional chemical synthesis method, which greatly reduces the use of organic solvents and the emissions of the three wastes, and reduces the emissions of the three wastes and product costs by 30%. The successful implementation of this project will surely provide reference and demonstration for the development of green manufacturing technology for chiral drugs, and produce significant economic, social and environmental benefits.

Keyword:

Scan the QR code to read on your phone

11-17

Zhejiang Lepu Pharmaceutical Co., Ltd. signed an agreement with the Taizhou Research Institute of SUSTech to build a joint R&D center

On October 12, 2020, Zhejiang Lepu Pharmaceutical, Southern University of Science and Technology Taizhou Research Institute and Taizhou Aisente Technology Co., Ltd. held a joint R&D center signing ceremony in Zhejiang Lepu Pharmaceutical Co., Ltd. Ai Jianqi, Dean of Taizhou Research Institute of Southern University of Science and Technology, General Manager of Taizhou Ascent Technology Co., Ltd., Doctoral Supervisor Professor Zhang Xumu, and General Manager Hong Huabin of Zhejiang Lepu Pharmaceutical Co., Ltd. attended the signing ceremony.
11-17

Zhejiang Lepu Pharmaceutical starts weekly learning meetings

In order to accelerate the legalization and normalization of the second phase of the technical transformation project for solid preparations with an annual output of 1.5 billion (tablets, granules), according to relevant regulations, on October 13, 2020
11-17

The second phase of Lepu Pharmaceutical Technology's annual output of 1.5 billion (tablets, granules) solid preparation technological transformation project passed the safety completion acceptance

In order to accelerate the legalization and normalization of the second phase of the technical transformation project for solid preparations with an annual output of 1.5 billion (tablets, granules), according to relevant regulations
11-17

Shen Yinchu, academician of the Chinese Academy of Engineering, came to Zhejiang Lepu to guide scientific research

On September 30th, Shen Yinchu, academician of the Chinese Academy of Engineering, and his entourage came to our company to guide scientific research work. After visiting the company's exhibition hall and preparation production workshop
11-17

Zhejiang Lepu Pharmaceutical organizes party members to attend party classes

On August 21, Zhejiang Lepu Pharmaceutical organized more than 50 middle and high-level party members of the company to attend party classes. General Manager Hong Huabin gave a profound party lesson to party members and cadres at the meeting.
11-17

Leaders of Zhejiang Food and Drug Administration investigate Zhejiang Lepu Pharmaceutical

On September 17, Shao Yuanchang, deputy director of Zhejiang Provincial Drug Administration, accompanied by leaders of the two-level market supervision administration of Taizhou City, went to Zhejiang Lepu Pharmaceutical to conduct the "three services" of serving enterprises, serving the masses, and serving the grassroots. Research work.
Previous page
1
2
这是描述信息

Support Hotline

QR code

Scan to enter

Copyright © 2021 Zhejiang LePu Pharmaceutical Co., Ltd. All rights reserved 浙ICP备17026965号 Powered by www.300.cn